News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
AstraZeneca PLC Bloodthinner, Brilinta Goes Before U.S. Experts Today
July 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- AstraZeneca Plc's experimental blood thinner goes before U.S. advisers on Wednesday, facing questions over why a trial of the potential blockbuster drug failed to cut heart attacks and deaths in North American patients.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Approvals
Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug
March 30, 2026
·
3 min read
·
Tristan Manalac
Government
After Speaking out of Turn, Malone Steps Down From Vaccine Committee
March 27, 2026
·
2 min read
·
Tristan Manalac
Gene therapy
Rocket’s Gene Therapy Wins FDA Greenlight, Clearing Way for Future Products
March 27, 2026
·
2 min read
·
Tristan Manalac
Approvals
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA’s Hunter Syndrome Nod
March 26, 2026
·
3 min read
·
Tristan Manalac